AstraZeneca is likely to run an additional global trial to assess its COVID-19 vaccine’s efficacy using a lower dosage. Instead of adding the trial to an ongoing U.S. process, AstraZeneca might launch a fresh study to evaluate a lower dosage of its vaccine that performed better than a full dosage, Pascal Soriot, AstraZeneca’s CEO, told Bloomberg News, amid questions over the results of its late-stage study.
The company wants the new test to confirm the 90% efficacy rate that the shot showed in a portion of an existing trial, reported Bloomberg.
AstraZeneca’s COVID-19 vaccine is one of three that could get approved before the end of the year, as Reuters noticed. It is also the only vaccine that Brazil‘s government has deals to acquire so far.